210 related articles for article (PubMed ID: 33722858)
1. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
[TBL] [Abstract][Full Text] [Related]
2. Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV; Bodyak ND; Yin M; Thomas JD; Clardy SM; Conlon PR; Stevenson CA; Uttard A; Qin L; Gumerov DR; Ter-Ovanesyan E; Bu C; Johnson AJ; Gurijala VR; McGillicuddy D; DeVit MJ; Poling LL; Protopopova M; Xu L; Zhang Q; Park PU; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):885-895. PubMed ID: 33722857
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
6. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
7. ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
Smith RA; Zammit DJ; Damle NK; Usansky H; Reddy SP; Lin JH; Mistry M; Rao NS; Denis LJ; Gupta S
Mol Cancer Ther; 2021 Aug; 20(8):1327-1337. PubMed ID: 34045226
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.
Xu L; Zhang Z; Xu S; Xu J; Lin ZJ; Lee DH
J Pharm Biomed Anal; 2019 Sep; 174():441-449. PubMed ID: 31220702
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
[TBL] [Abstract][Full Text] [Related]
10. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
11. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
12. Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer.
Minnix M; Li L; Yazaki P; Chea J; Poku E; Colcher D; Shively JE
Cancer Med; 2020 Jul; 9(13):4756-4767. PubMed ID: 32368864
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
14. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
Wang X; Ma D; Olson WC; Heston WD
Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
[TBL] [Abstract][Full Text] [Related]
17. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]